Prokidney (PROK) Debt Ratio (2021 - 2022)
Prokidney's (PROK) quarterly Debt Ratio came in at 0.0 in Q2 2022, down 99.22% year-over-year from 0.04 in Q2 2021, and up 84.78% quarter-over-quarter from 0.0 in Q1 2022.
Powered by 
Analysis
Prokidney (PROK) Debt Ratio (2021 - 2022) Analysis & Trends
Prokidney (PROK) has reported Debt Ratio for 2 consecutive years, with 0.0 the latest figure, recorded in Q2 2022.
- On a quarterly basis, Debt Ratio fell 99.22% year-over-year to 0.0 in Q2 2022; TTM through Jun 2022 was 0.0, a 99.22% decrease from a year earlier, with the FY2021 full-year figure at 0.0, changed N/A from the prior year.
- Debt Ratio was 0.0 for Q2 2022 at Prokidney, up from 0.0 in the prior quarter.
- Over five years, Debt Ratio peaked at 0.04 in Q2 2021 and troughed at 0.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 0.22 |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 0.09 |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 0.05 |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 0.08 |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 0.55 |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 0.27 |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | 0.04 |